Business
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Actively recruiting clinical trials in neurology and rheumatology with KYV-101No severe ICANS or CRS reported in first 36 autoimmune disease patients treated
About this update from Kyverna Therapeutics, Inc.
[{"type":"text","content":"Actively recruiting clinical trials in neurology and rheumatology with KYV-101No severe ICANS or CRS reported in first 36 autoimmune disease patients treated with KYV-101Received FDA RMAT Designation for KYV-101 for treatment of patients with Stiff-Person SyndromeReceived FDA RMAT Designation for KYV-101 for treatment of patients with Myasthenia GravisReported clinical experience with first KYV-101 patient disease-free at 1 year after treatmentEMERYVILLE, Calif., Aug. 12, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the second quarter ended June 30, 2024.\n\n \n \n \n \n \n \n\n \n\"We have shown promising initial safety and efficacy for our lead product candidate, KYV-101, and continue to lead the way in bringing CAR T-cell therapies to patients with autoimmune diseases in the US and Europe,\" said Peter Maag, Chief Executive Officer of Kyverna. \"We believe that KYV-101 brings the power of CD19-directed CAR T therapy to deliver deep tissue-based B cell depletion using a fully human CAR and CD28 costimulatory domain designed by the NIH to improve tolerability. We look forward to sharing more clinical data throughout the rest of 2024 as we strive to fulfill our promise to bring hope to patients living with autoimmune disorders.\"\nSecond Quarter 2024 and Recent Business Highlights\nPresented clinical data showing use of the CAR in KYV-101 across 50 patients including 15 different autoimmune conditions at CAR T centers in the US and EuropeExpanded KYV-101 safety experience with no severe ICANS or CRS Grade ≥3 reported in 36 autoimmune patients treated as of July 31, 2024, using CAR construct designed by the NIH to improve tolerabilityReceived two U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designations for KYV-101: one for the treatment of patients with Stiff-Person Syndrome, and one for the treatment of patients with myasthenia gravis, building on the emerging body of clinical evidenceAchieved 100% manufacturing success rate across all 36 cumulative autoimmune patients treated with KYV-101 as of July 31, 2024Reported clinical experience of a myasthenia gravis patient who is now free of disea...